Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA
| Autor: | Martine Piccart, Dimitrios Zardavas, Christelle Senterre, Evandro de Azambuja, Felipe Ades, R. A. Popescu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Economics
Cancer Treatment Psychologie appliquée Social Sciences lcsh:Medicine Pharmacology Geographical Locations 0302 clinical medicine Trastuzumab Epidemiology of cancer Breast Tumors Medicine and Health Sciences 030212 general & internal medicine Life saving lcsh:Science skin and connective tissue diseases media_common Multidisciplinary Pharmaceutics Commerce Research Assessment Sciences bio-médicales et agricoles Europe Oncology 030220 oncology & carcinogenesis Biologie medicine.drug Research Article Procurement Drug Research and Development Antineoplastic Agents Marketing authorization Research and Analysis Methods 03 medical and health sciences Breast cancer Drug Therapy Diagnostic Medicine Breast Cancer medicine Cancer Detection and Diagnosis media_common.cataloged_instance European Union European union neoplasms business.industry lcsh:R Cancers and Neoplasms medicine.disease United States People and Places lcsh:Q National registry business Demography |
| Zdroj: | PloS one, 12 (3 PLoS ONE, Vol 12, Iss 3, p e0172351 (2017) PLoS ONE |
| Popis: | Background The development of trastuzumab is considered to be one of the greatest improvements in breast cancer treatment in recent years. This study aims to evaluate changes in the uptake of trastuzumab over the last 12 years and to determine whether its use is proportional to patient needs in the European Union and the USA. Methods Using national registry data, the number of new cases of HER2-positive breast cancer patients per year was estimated. The number of likely trastuzumab treatments per year was estimated using trastuzumab procurement data for each country. Results Western Europe and the USA show increasing procurement level of trastuzumab over the years studied, reaching proportional of use of trastuzumab few years after its marketing authorization in the early 2000's. After the approval in the adjuvant setting, in the year 2006, it was observed underuse of trastuzumab given the increase of the number of patients in need of treatment. Proportional use was shortly met after a couple of years. Few countries in Eastern Europe acquired the needed quantity of trastuzumab, with procurement levels starting to increase only after approval in the adjuvant setting in 2006. Conclusion Significant differences in trastuzumab procurement are observed between Western Europe, the USA and Eastern Europe, with the latter geographic region acquiring insufficient amounts of the drug required to treat all patients in need. SCOPUS: ar.j info:eu-repo/semantics/published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|